Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis: A Meta-analysis
- Authors
- Lee, Young-Ho; Bae, Sang-Cheol; Song, Gwan-Gyu
- Issue Date
- 7월-2012
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- Omega-3 polyunsaturated fatty acids; Rheumatoid arthritis
- Citation
- ARCHIVES OF MEDICAL RESEARCH, v.43, no.5, pp.356 - 362
- Indexed
- SCIE
SCOPUS
- Journal Title
- ARCHIVES OF MEDICAL RESEARCH
- Volume
- 43
- Number
- 5
- Start Page
- 356
- End Page
- 362
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/108054
- DOI
- 10.1016/j.arcmed.2012.06.011
- ISSN
- 0188-4409
- Abstract
- Background and Aims. We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at >= 2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA). Methods. The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD). Results. Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95% CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I-2 = 0%). Tender joint count (SMD -0.214, 95% CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95% CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95% CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95% CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance. Conclusions. This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA. (C) 2012 IMSS. Published by Elsevier Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.